Michael Hayden's Insider Trades & SAST Disclosures
Michael Hayden's most recent trade in Ionis Pharmaceuticals Inc was a trade of 15,000 Common Stock done at an average price of $31.9 . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Hayden.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 31.86 per share. | 01 May 2025 | 15,000 | 50,219 (0%) | 0% | 31.9 | 477,900 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 56,400 | 56,400 | - | - | Stock Option (Right to Buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 36.23 per share. | 23 Dec 2024 | 2,500 | 35,219 (0%) | 0% | 36.2 | 90,583 | Common Stock |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 36.20 per share. | 23 Dec 2024 | 2,500 | 32,719 (0%) | 0% | 36.2 | 90,496 | Common Stock |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 10,111 | 10,111 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 4,079 | 8,756 | - | - | Restricted Stock Unit | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 163,934 | 660,979 | - | - | Share option (right to buy) | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 45,150 | 45,150 | - | - | Stock Option (Right to Buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 5.90 per share. | 08 Aug 2023 | 30,000 | 1,303,397 | - | 5.9 | 177,000 | Common Shares |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 30,219 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 4,677 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 24,886 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 10,010 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 10,321 | 10,321 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 4,677 | 11,787 | - | - | Restricted Stock Unit | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 27,400 | 27,400 | - | - | Stock Option (Right to Buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 47,231 | 497,045 | - | - | Share Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 1,777 | 23,109 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 1,777 | 7,110 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 10,664 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 19,555 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 1,777 | 21,332 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 1,777 | 8,887 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 5,333 | 15,997 | - | - | Restricted Stock Unit | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 16.15 per share. | 30 Mar 2022 | 61,538 | 61,538 (0%) | 0% | 16.2 | 993,839 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 3.48 per share. | 30 Mar 2022 | 10,000 | 93,978 (0%) | 0% | 3.5 | 34,750 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 2.67 per share. | 30 Mar 2022 | 10,000 | 103,978 (0%) | 0% | 2.7 | 26,700 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 30 Mar 2022 | 6,250 | 83,978 (0%) | 0% | 3.6 | 22,625 | Common Stock |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 45,532 | 449,814 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 34,282 | 674,282 | - | - | Share option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 1,777 | 10,664 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 1,777 | 14,222 (0%) | 0% | 0 | Common Stock | |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.73 per share. | 13 Sep 2021 | 270,000 | 1,273,397 | - | 17.7 | 4,787,100 | Common Shares |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 270,000 | 270,000 | - | - | Share option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 14,219 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 10,667 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 12,441 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 12,445 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 5,333 | 19,552 | - | - | Restricted Stock Unit | |
| AbCellera Biologics Inc | Michael Hayden | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 22 Jun 2021 | 100,000 | 1,003,397 | - | 25.5 | 2,550,000 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 18 May 2021 | 3,500 | 116,206 (0%) | 0% | 3.9 | 13,475 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 3,500 | 0 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2021 | 60,820 | 27,647 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 23 Feb 2021 | 60,820 | 60,820 (0%) | 0% | 1.9 | 117,383 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2021 | 13,637 | 22,730 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.11 per share. | 23 Feb 2021 | 13,637 | 80,904 (0%) | 0% | 3.1 | 42,411 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 23 Feb 2021 | 6,447 | 67,267 (0%) | 0% | 1.9 | 12,443 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2021 | 6,447 | 2,933 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. | 16 Feb 2021 | 30,864 | 92,076 (0%) | 0% | 2.7 | 82,716 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 30,864 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 16 Feb 2021 | 10,288 | 61,212 (0%) | 0% | 3.7 | 37,757 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 10,288 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,144 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. | 16 Feb 2021 | 5,144 | 112,706 (0%) | 0% | 2.7 | 13,786 | Common Shares |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.44 per share. | 29 Jan 2021 | 50,000 | 50,000 (0%) | 0% | 5.4 | 272,000 | Common Shares |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.06 per share. | 29 Jan 2021 | 30,000 | 80,000 (0%) | 0% | 6.1 | 181,800 | Common Shares |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 29 Jan 2021 | 15,000 | 95,000 (0%) | 0% | 6.4 | 96,300 | Common Shares |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.33 per share. | 15 Dec 2020 | 270,000 | 985,750 | - | 0.3 | 89,100 | Common Shares |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 270,000 | 540,000 | - | - | Stock Option (right to buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | 15 Dec 2020 | 117,647 | 1,103,397 | - | - | Common Shares | ||
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 15 Dec 2020 | 73,665 | 118,245 | - | 20 | 1,473,300 | Common Shares |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 1,778 | 3,554 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 1,778 | 5,334 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 5,333 | 5,333 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 1,778 | 3,556 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 1,778 | 5,332 | - | - | Restricted Stock Units | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges